LABU icon

Direxion Daily S&P Biotech Bull 3X Shares

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 50%
Negative

Positive
24/7 Wall Street
1 month ago
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Triple-leveraged ETFs aren't for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull 3X Shares (NASDAQ:LABU) offers the most aggressive way to capture that move.
Triple-Leveraged Biotech ETF Doubles as Regulatory Winds Shift in 2026
Neutral
Benzinga
2 months ago
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
Although the equities market often embodies chaos and capricious non-linearity, few sectors witness as much kinetic wildness like biotechnology. At its core, biotech represents an innovative push toward addressing the human condition — which is often found to be shockingly frail.
Navigate Biotech's Crosscurrents With Direxion's LABU And LABD ETFs
Neutral
ETF Trends
3 months ago
Top Performing Leveraged/Inverse ETFs: 11/16/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 11/16/2025
Positive
ETF Trends
3 months ago
New FDA Director Could Sway Biotech ETFs
Biotech stocks could sway toward the upside with the appointment of a new director at the Federal Drug Administration's Center for Drug Evaluation and Research. Dr. Richard Pazdur will take the reigns, bringing 26 years of related industry experience.
New FDA Director Could Sway Biotech ETFs
Positive
Seeking Alpha
3 months ago
Investing In Health Stocks - How Policy Clarity Is Opening Doors
The healthcare sector has experienced one of its most significant de-ratings in 35 years, with valuations now at a 30% discount to the broader market. Healthcare trades at historical valuation discounts across multiple metrics.
Investing In Health Stocks - How Policy Clarity Is Opening Doors
Positive
ETF Trends
5 months ago
As M&A Deals Rise, Can Biotech Pharma Break Loose?
After a relatively sluggish 2024 for mergers & acquisitions (M&A) activity in the biopharma sector, the environment could be more conducive for deals in the rest of 2025. The industry, like the rest of the capital markets, will be keeping an eye on interest rates as monetary easing by the U.S.
As M&A Deals Rise, Can Biotech Pharma Break Loose?
Neutral
ETF Trends
5 months ago
Top Performing Leveraged/Inverse ETFs: 09/07/2025
Top Performing Levered/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 09/07/2025
Neutral
ETF Trends
6 months ago
Top Performing Leveraged/Inverse ETFs: 08/17/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 08/17/2025
Neutral
Seeking Alpha
9 months ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Neutral
ETF Trends
10 months ago
Top Performing Leveraged/Inverse ETFs: 04/20/2025
Top Performing Leveraged/Inverse ETFs Last Week These were last week's top performing leveraged and inverse ETFs. Note that because of leverage, these kinds of funds can move quickly.
Top Performing Leveraged/Inverse ETFs: 04/20/2025